Status
Conditions
Treatments
About
Full description
• Prospective, multi-center single-arm observational study
Screening (day 0):
Medical history and demography of the patient reviewed Inclusion/exclusion eligibility will be checked Physical examination (Height, weight)
Laboratory test
BUN, eGFR, Cr. Hb, WBC, platelet Lipid level (total cholesterol, LDL-C, triglyceride, HDL-C) Ankle-brachial index Imaging study (CT/MR angiography, Doppler ultrasound, or catheter angiography) Medication
Enrollment (day 0):
Post PTA (Day 1 ~3):
Adverse event Ankle-brachial index
Laboratory test:
BUN, eGFR, Cr. Hb, WBC, platelet Concomitant medication Regular Follow-up Visits Visit 1 (post-PTA 30±14 days)
BUN, eGFR, Cr.
Hb, WBC, platelet 3) Concomitant medication 4) Adverse event Visit 2 (post-PTA 6 months ± 30 days)
Symptoms: Rutherford class Ankle-brachial index Concomitant medication Adverse event Visit 3 (post-PTA 12 months ± 60 days) Symptoms: Rutherford class Ankle-brachial index Duplex ultrasound, CT, or catheter angiography Biplane radiograph of femur for evaluation of stent fracture Laboratory test BUN, eGFR, Cr. Hb, WBC, platelet
Lipid level (total cholesterol, LDL-C, triglyceride, HDL-C) 6)Concomitant medication 7) Adverse event Visit4 (post-PTA 24 months ± 60 days)
Symptom: Rutherford category Adverse events
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 19 years of older
Symptomatic peripheral artery disease:
Femoropopliteal artery lesions with stenosis > 50%
ABI < 0.9 before treatment
Patents treated with ELUVIA stent for femoropopliteal artery disease
Patients with signed informed consent
Exclusion criteria
100 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal